Friday, 16 October 2026European Markets

AXWAY SOFTWARE Stock Bullish By 32% In The Last 21 Sessions

Loading stream...

(VIANEWS) - Shares of AXWAY SOFTWARE (CAC 40: AXW.PA) jumped by a staggering 32.55% in 21 sessions from $17.05 to $22.60 at 16:53 EST on Tuesday, following the last session's upward trend. CAC 40 is falling 0.07% to $7,132.35, following the last session's downward trend.

About AXWAY SOFTWARE

Axway Software SA operates as an infrastructure software publisher in the Americas, France, rest of Europe, the Asia Pacific, and internationally. The company provides AMPLIFY, a platform that offers application integration, API management, managed file transfer, B2B-EDI integration, and digital finance solutions. It also offers specialized enterprise integration products to provide visibility, intelligence, and security throughout the digital ecosystem; counter threats before they happen; optimize business assets and resources; safeguard against risks; and improve operational performance, as well as provides managed cloud services. The company serves the automotive, banking and financial services, healthcare, insurance, life science, manufacturing and consumer packaged goods, retail, and transportation and logistics industries, as well as government and public sectors. Axway Software SA was incorporated in 2000 and is headquartered in Scottsdale, Arizona.

Earnings Per Share

As for profitability, AXWAY SOFTWARE has a trailing twelve months EPS of $0.46.

PE Ratio

AXWAY SOFTWARE has a trailing twelve months price to earnings ratio of 49.13. Meaning, the purchaser of the share is investing $49.13 for every dollar of annual earnings.

More news about AXWAY SOFTWARE (AXW.PA).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com